Risperidone. A review of its use in the management of the behavioural and psychological symptoms of dementia

Drugs and Aging

Volumn 16, Issue 6, 2000, Pages 451-471

  Bhana, Nila ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 2A RECEPTOR;

AGGRESSION; BEHAVIOR DISORDER; CLINICAL TRIAL; DEMENTIA; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; REVIEW; TARDIVE DYSKINESIA;

EID: 0033945520     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016060-00005     Document Type: Review

References (74)

1. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipychotic. J Pharmacol Exp Ther 1988; 247: 661-70
2. Marder SR. Clinical experience with risperidone. J Clin Psychiatry 1996; 57 Suppl. 9: 57-61
3. Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48 (2): 253-73
4. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials [published erratum appears in J Clin Psychiatry 1998 Apr; 59 (4): 200]. J Clin Psychiatry 1997 Dec; 58: 538-46
5. Kumar V, Brecher M. Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients. J Clin Psychiatry 1999; 60 Suppl. 13: 5-9
6. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996 Apr; 16: 177-87
7. Finkel SI. Managing the behavioral and psychological signs and symptoms of dementia. Int Clin Psychopharmacol 1997 Sep; 12 Suppl. 4: S25-28
8. Sweet RA, Pollock BG. New atypical antipsychotics: experience and utility in the elderly. Drugs Aging 1998; 12 (2): 115-27
9. 2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology 1993; 110 (3): 265-72
10. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995 Feb; 15 Suppl. 1: 19-23
11. Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand Suppl 1995; 91 (388): 24-30
12. 2 and dopamine D2 receptors. Int Clin Psychopharmacol 1995; 10 (1): 19-30
13. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124 (1-2): 57-73
14. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993; 38 Suppl. 3: S80-8
15. Leysen JE, Janssen PMF, Gommeren W, et al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992; 41: 494-508
16. Lemmens P, Brecher M, Van-Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999 Mar; 99: 160-70
17. Dugovic C, Wauquier A, Janssen PAJ. Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat. Neuropharmacology 1989; 28: 1431-3
18. Kopala LC, Honer WG. The use of risperidone in severely demented patients with persistent vocalizations. Int J Geriatr Psychiatry 1997 Jan; 12: 73-7
19. Madhusoodanan S, Brenner R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 1999 Aug; 12: 135-50
20. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999 Sep; 53 (2): 946-55
21. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999 Feb; 60: 107-15
22. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999 Feb; 19: 57-61
23. Kim YK, Kim L, Lee MS. Risperidone and associated amenorrhea: a report of 5 cases. J Clin Psychiatry 1999 May; 60: 315-7
24. Cardoni AA. Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother 1995; 29 (6): 610-8
25. Huang M-L, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54 (3): 257-68
26. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995 Dec; 122 (3): 223-9
27. Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 1998 Oct; 139 (4): 356-63
28. van Beijsterveldt LEC, Geerts RJF, Leysen JE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 1994; 114 (1): 53-62
29. Mannens G, Meuldermans W, Snoeck E, et al. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology 1994 May; 114: 566-72
30. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 1998; 57 (1): 107-16
31. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998 Spring; 6: 127-35
32. Mannens G, Huang M-L, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21 (6): 1134-41
33. Pesco-Koplowitz L, Parier J-L, Zhao Q, et al. Pharmacokinetics of combined risperidone/donepezil administration [poster]. Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico
34. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging 1998 Nov; 13: 391-411
35. Class CA, Schneider L, Farlow MR. Optimal management of behavioural disorders associated with dementia. Drugs Aging 1997 Feb; 10: 95-106
36. Burgio L. Direct observation of behavioral disturbances of dementia and their environmental context. Int Psychogeriatr 1996; 8 Suppl. 3: 343-6
37. Reisberg B, Borenstein J, Salob SP, et al. Behavioural symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 Suppl.: 9-15
38. Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly. J Am Geriatr Soc 1986; 36: 711-21
39. De Smedt G, De Deyn PP. Long-term safety and efficacy of risperidone in the treatment of behavioural disturbances in elderly patients with dementia [poster]. Annual Meeting of the American College of Clinical Pharmacy; 1998 Nov 8-11; Cincinnati (OH)
40. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. In press
41. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997 Mar; 9: 65-8
42. Goldberg RJ. Long-term use of risperidone for the treatment of dementia-related behavioural disturbances in a nursing home population. Int J Geriatr Psychopharmacol. In press
43. Frenchman IB, Prince T. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr 1997 Dec; 9: 431-5
44. Frenchman IB, Pieniro M, Stenstrom S, et al. Comparison of atypical agents and haloperidol in nursing home patients [abstract]. American Psychiatric Association Annual Meeting: New Research Program & Abstracts; 1999 May 15; Washington, DC: 208
45. Zarate Jr CA, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997 Jul; 58: 311-7
46. Risperdal approved for dementia. Scrip 1998 Nov 6 (2385): 22
47. Herrmann N, Rivard M-F, Flynn M, et al. Risperidone for the treatment of behavioral disturbances in dementia: a case series. J Neuropsychiatry Clin Neurosci 1998; 10: 220-3
48. Chopra A, Scheinthal SM, Shah C, et al. Atypical antipsychotic drugs in the management of aggression in elderly patients with dementia in a special care unit [abstract]. J Am Geriatr Soc 1998 Sep; 46: S98
49. Tariot PN. Treatment of agitation in dementia. J Clin Psychiatry 1999; 60 Suppl. 8: 11-20
50. Brennan R, Lonergan V, Quilinan T, et al. Case studies on the use of risperidone for the treatment of agitation in elderly patients with dementia. J Drug Assess 1999: 247-53
51. Howard R, David A, Woodruff P, et al. Seeing visual hallucinations with functional magnetic resonance imaging. Dementia Geriatr Cogn Disord 1997; 8 (2): 73-7
52. Schneider LS. Pharmacologic management of psychosis in dementia. J Clin Psychiatry 1999; 60 Suppl. 8: 54-60
53. Irizarry MC, Ghaemi SN, Lee-Cherry ER, et al. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci 1999; 11 (3): 336-42
54. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
55. Brecher M, Kane JM, Okamoto A, et al. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year [poster]. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto (ONT)
56. Fischer P, Tauscher J, Küfferle B. Risperidone and tardive dyskinesia in organic psychosis [letter]. Pharmacopsychiatry 1998 Mar; 31: 70-1
57. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33 (1): 73-85
58. Jeste DV, Lacro IP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999 Jun; 47: 716-9
59. Wilson JG, Pinkerton A, Miller MJ, et al. An assessment of tardive dyskinesia in elderly patients treated with haloperidol, risperidone and olanzapine [abstract]. In: American Psychiatric Association Annual Meeting: New Research Program & Abstracts; 1999 May 15; Washington, DC: 264
60. Bajjoka I, Patel T, O'Sullivan T. Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med 1997 Nov; 30: 698-700
61. Gleason PP, Conigliaro RL. Neuroleptic malignant syndrome with risperidone. Pharmacotherapy 1997 May-Jun; 17: 617-21
62. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome [7]. Lancet 1994; 344 (8931): 1228-9
63. Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8: 151-9
64. Acri AA, Henretig FM. Effects of risperidone in overdose. Am J Emerg Med 1998 Sep; 16: 498-501
65. Himstreet JE, Daya M. Hypotension and orthostasis following a risperidone overdose [letter]. Ann Pharmacother 1998 Feb; 32: 267
66. Kuspis D, Dean B, Krenzelok EP. Risperidone overdose assessment [abstract]. J Toxicol Clin Toxicol 1995 Sep; 33: 552
67. Ott A, Breteler MMB, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education: the Rotterdam study. BMJ 1995 Apr 15; 310: 970-3
68. Hikal AH, Hikal EM. Dementia in the elderly. Drug Topics 1998; 142 (20): 81-90
69. Fratiglioni L, De Ronci D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999 Nov 15; 15 (5): 365-75
70. Dooley M, Lamb HM. Donepezil: a review of its use in Alzheimer's disease. Drugs Aging 2000; 16 (3): 199-226
71. Stoppe G, Brandt CA, Staedt JH. Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs Aging 1999 Jan; 14: 41-54
72. Lanctôt KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59 (10): 550-61
73. Alexopoulos GS, Silver JM, Kahn DA, et al., editors. Treatment of agitation in older persons with dementia. Minneapolis (MI): Postgraduate Medicine; McGraw-Hill, 1998
74. Defilippi JL, Crismon ML. Antipsychotic agents in patients with dementia. Pharmacotherapy 2000; 20 (1): 23-33